Table 2. Frequency of the outcomes by study group at the end of the study period.
| Outcomes | BRCA mutation with RRBSO (n=329) | BO without BRCA mutation (n=3,290) | Intact ovaries without BRCA mutation (n=3,290) | |
|---|---|---|---|---|
| Bone fractures | 44 (13.4%) | 616 (18.7%) | 445 (13.5%) | |
| Hip fracture | ≤5 | 21 (0.6%) | 14 (0.4%) | |
| Vertebral fracture | ≤5 | 36 (1.1%) | 31 (0.9%) | |
| Forearm fracture | 10 (3.0%) | 132 (4.0%) | 82 (2.5%) | |
| Humerus fracture | ≤5 | 33 (1.0%) | 31 (0.9%) | |
| Pelvic fracture | ≤5 | 16 (0.5%) | 13 (0.4%) | |
| Other fractures | 27 (8.2%) | 399 (12.1%) | 299 (9.1%) | |
| Osteoporosis | 22 (6.7%) | 127 (3.9%) | 45 (1.4%) | |
| DEXA scan | 152 (46.2%) | 761 (23.1%) | 335 (10.2%) | |
| Bisphosphonates | 27 (8.2%) | 180 (5.5%) | 60 (1.8%) | |
| No. of women who had DEXA scan | 152 | 761 | 335 | |
| Osteoporosis | 22 (14.5%) | 108 (14.2%) | 38 (11.3%) | |
| No. of women with osteoporosis diagnosis | 22 | 127 | 45 | |
| Bisphosphonates | 8 (36.4%) | 65 (51.2%) | 21 (46.7%) | |
RRBSO, risk-reducing bilateral salpingo-oophorectomy; BO, bilateral oophorectomy; DEXA, dual-energy X-ray absorptiometry.
*p-values for the crude incidences were not provided, as this comparison between the groups is not meaningful due to differences in the follow-up time.